Naomi Aronson, PhD Executive Director of Clinical Evaluation Innovation & Policy Office of Clinical Affairs Blue Cross, Blue Shield Association
Discover which therapeutic modalities and targets will deliver genuine commercial success at the only translational/clinical strategy event bringing together pharma and biotech decision-makers from the autoimmune disease and inflammation fields. Find out how industry leaders are capitalizing on emerging tools and pathways to deliver more efficacious anti-inflammatory drugs with commercial potential across multiple therapeutic areas. The Autoimmune & Inflammation Leaders Forum arms attendees with strategic insights to help them effectively differentiate the next wave of therapeutics, preparing them for success in an increasingly competitive market environment.
Recognized as the leader by the leaders, this is the event of choice for senior translational and clinical oncology R&D executives driving the development, registration and launch of novel cancer therapeutics of all classes, plus companion diagnostics. The Oncology Leaders Forum provides the perfect environment to 'sanity check' your own strategies whilst establishing and developing relationships with potential partners - for instance, in the burgeoning fields of immunoncology, combination therapy development or Big Data.
THE meeting place for senior R&D executives from companies large and small tasked with de-risking drug development whilst driving innovation across the cardiometabolic field. Pinpoint the most promising opportunities in type 1 and 2 diabetes, obesity, diabetic complications and Dyslipidemia, and establish appropriate product profiles to efficiently and effectively demonstrate positive outcomes. The Metabolic Leaders Forum identifies for drug development executives the specific areas of greatest unmet need and opportunity in a therapeutic area which is beginning to move again in innovation terms after years of relative stagnation. It also proffers practically-applicable strategic solutions to the challenges in meeting safety and efficacy requirements for novel therapeutics.
Europe's Global Vaccine Partnering event, VAX 1-2-1 builds upon the long-standing and successful Phacilitate Vaccine Forum and Partnering for Emerging Markets event series. For a sector overburdened by 'me-too' events, VAX 1-2-1 delivers a unique new concept and opportunity, combining unmissable learning and partnering opportunities for the global industry's corporate, manufacturing and R&D executive, plus key external stakeholders including NGOs and public and private sector investors. Incorporating a wide range of novel formats and an innovative overall event layout, attendees will experience an array of environments in a single location, all of them geared to promote interaction and to put the onus on developing both the strategic insight and contacts required to drive vaccine R&D, manufacturing and commercial business models forward worldwide.
Launching in 2015, Cell & Gene Therapy Europe offers a brand new knowledge exchange, benchmarking and networking opportunity for the global sector. What’s different? - Specific European content focus. o Agenda focuses specifically on ‘Euro-centric’ topics, issues and opportunities: from detailed analysis of European regulatory pathways, to troubleshooting clinical development on the continent, to clarification of funding availability/access on a nation-by-nation basis. - Attendee profile. o 80%+ of our attendees in Barcelona will hail from Europe. (Compared to typically 15% maximum at our Washington, DC meeting) A new audience = more contacts, new learnings for you!
- THE Big Data meeting for drug development budget holders - Transforming theory into action, value and competitive advantage - Capitalizing on the promise of real world evidence throughout the clinical development process In the wake of the highly successful launch of the Big Data Leaders Forum in October 2014, Phacilitate received extremely positive feedback that a specific focus on the application of Big Data-derived insights in translational and clinical R&D was a strong feature and differentiator of the event. In 2015, the event is renamed ‘Big Data in Clinical Development’ - a signal of intent to provide even more real-world examples of strategies improving decision-making during this most risky and expensive, but also potentially rewarding stage of the overall drug discovery, development and commercialization process. Attendees will receive unique insights into where the major industry players are placing their bets to ensure Big Data in drug development provides a critical source of competitive advantage for years to come. They will also discover the right questions to ask of Big Data throughout the product lifecycle in order to build a more comprehensive body of real world evidence, and a better prediction of value. Meet the senior leaders representing all of the functions that directly influence - and ultimately make- the decision of how individual pharma, CRO and biotech companies will harness the potential of Big Data to improve their clinical development strategies and results.
Brand new for 2015, Phacilitate is delighted to present a meeting specifically aimed at the pharma, biotech and healthcare sector leaders currently implementing strategies to harness the potential of eHealth solutions, including mHealth devices. The meeting will be collocated with Big Data in Clinical Development - all attendees will enjoy equal access to attendees from both conferences, and all networking breaks, functions and the online 121 Partnering Tool will be shared. Phacilitate looks forward to expanding the event’s audience to include the payers, KOLs, pharma/biotech leaders, eHealth and mHealth technology/service providers, IT infrastructure companies and other key stakeholders who between them will dictate the shape of the healthcare delivery model for years to come. Agenda research is now underway for the inaugural Phacilitate eHealth event - contact us today to register your interest and have your say on preferred topics and speakers!
World leading. - Longest established – 12th Annual in 2016 - Largest – 150+ speakers, 600+ attendees, 60+ exhibitors - More decision-makers – 80% Director level+ For Phacilitate, Washington 2016 is all about building on this position of strength to deliver the undisputed leader in novel biologics industry events worldwide. • Significantly larger expo & 121 Partnering Area offers more Private Meeting Booths and exciting new features: o Innovation Accelerator Theatre - brings the agenda to the expo floor o Regional Pavillions - helping ensure Washington 2016 is number 1 globally • Expanded agenda – more in-depth coverage of the key manufacturing, logistical, R&D and regulatory challenges and solutions • More interactive formats – ‘Interactive Hours’ every day, Tech Room Demonstrations, Roundtables, ‘Drop-in Clinics’ and more. • Stars of the Future – new feature welcomes the next generation of innovation and talent to join in the debate shaping the future of the Cell & Gene Therapy and Immunotherapy industries. Guarantee your place, optimize your involvement, maximize your ROI. Contact Phacilitate today!
Mark Trusheim Visiting Scientist MIT Sloan School of Management
Perry Karsen Chief Executive Officer Celgene Cellular Therapeutics
David Hall Chief Executive Officer Replicel
James L. Gulley, MD, PhD, FACP Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Center for Cancer Research National Cancer Institute